Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), drawn from the whole corpus: 41 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
15 medicines on record are linked to one of the types below rather than to Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) itself. Grouped by the type that holds them; each list opens that type's own page.
Five-year survival under 40% for PTCL-NOS with no new first-line regimen for non-CD30 disease.
Randomised evidence for transplant consolidation is lacking.
T-cell CAR-T faces fratricide and T-cell aplasia.
Most subtypes too rare for conventional phase 3 trials.
Also on OnCo: Find a trial · Expert centres.
Almost nothing given in peripheral T-cell lymphoma rests on a randomised trial. CHOP is the default without ever having been shown superior to anything; CHOEP rests on a retrospective subgroup; autologous transplant consolidation in first remission rests on a single-arm study and registry comparisons that select for the patients who were going to do well.
Adding romidepsin to CHOP failed in Ro-CHOP and the indication was withdrawn, leaving the CD30-negative nodal T-cell lymphomas with no advance since CHOP itself.
Extranodal NK/T-cell lymphoma and adult T-cell leukaemia/lymphoma are common in east Asia, the Caribbean and west Africa and rare in the countries that run most trials, so their evidence base is thin in exactly the places where patients are treated outside those regions.
Also on OnCo: Find a trial · Expert centres.
Valemetostat is approved in Japan for relapsed adult T-cell leukaemia/lymphoma and peripheral T-cell lymphoma and has no record in this corpus and no approval in the United Kingdom or the United States at the time of writing, which is a gap rather than a judgement.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 26 changes by month →When this page itself was last checked or edited.
Relapsed or refractory peripheral T-cell lymphoma
Confirmatory Ro-CHOP trial negative.
First-line CD30+ peripheral T-cell lymphoma with CHP (ECHELON-2)
Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy
A+CHP improved progression-free and overall survival over CHOP in CD30-positive peripheral T-cell lymphoma; approved in November 2018.